PNPLA3 Risk Allele Association With ALT Response to Semaglutide Treatment.
作者信息
Urias Esteban, Tedesco Nicholas R, Oliveri Antonino, Raut Chinmay, Speliotes Elizabeth K, Chen Vincent L
机构信息
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
出版信息
Gastroenterology. 2024 Mar;166(3):515-517.e2. doi: 10.1053/j.gastro.2023.11.018. Epub 2023 Nov 14.
Abstract
摘要
相似文献
1
PNPLA3 Risk Allele Association With ALT Response to Semaglutide Treatment.PNPLA3风险等位基因与司美格鲁肽治疗的ALT反应的关联
Gastroenterology. 2024 Mar;166(3):515-517.e2. doi: 10.1053/j.gastro.2023.11.018. Epub 2023 Nov 14.
2
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.司美格鲁肽对 2 型糖尿病和/或肥胖患者肝酶和炎症标志物的影响。
Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. Epub 2019 Jun 10.
3
A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children.载脂蛋白基因中的一个常见变异是台湾肥胖儿童非酒精性脂肪肝的一个危险因素。
J Pediatr. 2011 May;158(5):740-4. doi: 10.1016/j.jpeds.2010.11.016. Epub 2010 Dec 18.
4
Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis.PNPLA3基因rs738409多态性与非酒精性脂肪性肝病（NAFLD）易感性及严重程度的关联：一项荟萃分析。
Medicine (Baltimore). 2019 Feb;98(7):e14324. doi: 10.1097/MD.0000000000014324.
5
African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.非洲遗传血统与混合人群中非酒精性脂肪性肝病中 PNPLA3 G 等位基因的低频率相关。
Ann Hepatol. 2022 Nov-Dec;27(6):100728. doi: 10.1016/j.aohep.2022.100728. Epub 2022 Jun 13.
6
A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children.过氧化物酶体增殖物激活受体γ共激活因子 1α 基因中的常见变异与肥胖儿童的非酒精性脂肪性肝病有关。
Am J Clin Nutr. 2013 Feb;97(2):326-31. doi: 10.3945/ajcn.112.046417. Epub 2012 Dec 26.
7
PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis.载脂蛋白 L3 基因型和糖尿病可识别非酒精性脂肪性肝病患者发生肝硬化的高风险。
Gastroenterology. 2023 May;164(6):966-977.e17. doi: 10.1053/j.gastro.2023.01.040. Epub 2023 Feb 7.
8
A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.一种常见的 PNPLA3 变异与多民族生物库中 NAFLD 患者的诊断年龄相关。
J Hepatol. 2020 Jun;72(6):1070-1081. doi: 10.1016/j.jhep.2020.01.029. Epub 2020 Mar 5.
9
PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.PNPLA3表达与患有非酒精性脂肪性肝病的病态肥胖女性的肝脏脂肪变性有关。
Int J Mol Sci. 2016 Apr 27;17(5):630. doi: 10.3390/ijms17050630.
10
The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.膜结合 O-酰基转移酶 7 rs641738 变异与儿童非酒精性脂肪性肝病。
J Pediatr Gastroenterol Nutr. 2018 Jul;67(1):69-74. doi: 10.1097/MPG.0000000000001979.
引用本文的文献
1
Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes.荟萃分析：脂肪性肝病相关基因风险等位基因对纵向结局的影响。
Aliment Pharmacol Ther. 2025 Aug;62(3):244-276. doi: 10.1111/apt.70256. Epub 2025 Jun 28.
2
Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment.代谢功能障碍相关脂肪性肝病的人类遗传学：从变异到病因再到精准治疗
J Clin Invest. 2025 Apr 1;135(7):e186424. doi: 10.1172/JCI186424.
3
Cracking the code of HBV persistence: cutting-edge approaches to targeting cccDNA in chronic hepatitis B with or without pyogenic liver Abscesses.破解乙肝病毒持续感染的密码：针对合并或不合并化脓性肝脓肿的慢性乙型肝炎中cccDNA的前沿靶向方法
Front Med (Lausanne). 2025 Mar 17;12:1504736. doi: 10.3389/fmed.2025.1504736. eCollection 2025.
4
Global Epidemiology and Implications of I148M Variant in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis.代谢功能障碍相关脂肪性肝病中I148M变异体的全球流行病学及影响：一项系统评价和荟萃分析
J Clin Exp Hepatol. 2025 May-Jun;15(3):102495. doi: 10.1016/j.jceh.2024.102495. Epub 2024 Dec 26.
5
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application.非酒精性脂肪性肝炎相关肝病（MASLD）遗传学的最新进展：对疾病机制的见解及临床应用的新前沿
Hepatol Commun. 2025 Jan 7;9(1). doi: 10.1097/HC9.0000000000000618. eCollection 2025 Jan 1.
6
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.在患有代谢功能障碍相关脂肪性肝病的个体中，无论糖尿病和心脏代谢风险参数如何，司美格鲁肽均可带来相似的体重减轻：三项随机对照试验的事后分析
Diabetes Obes Metab. 2025 Feb;27(2):710-718. doi: 10.1111/dom.16065. Epub 2024 Nov 28.
7
PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.PNPLA3 I148M与环境触发因素相互作用导致人类疾病。
Liver Int. 2025 Mar;45(3):e16106. doi: 10.1111/liv.16106. Epub 2024 Nov 19.
8
The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.度拉糖肽对2型糖尿病患者糖化血红蛋白的影响与PNPLA3 Ι148Μ基因多态性相关。
Endocrine. 2025 Jan;87(1):73-78. doi: 10.1007/s12020-024-04007-8. Epub 2024 Aug 23.
本文引用的文献
1
The Michigan Genomics Initiative: A biobank linking genotypes and electronic clinical records in Michigan Medicine patients.密歇根基因组计划：一个将密歇根大学医学中心患者的基因型与电子临床记录相连接的生物样本库。
Cell Genom. 2023 Jan 31;3(2):100257. doi: 10.1016/j.xgen.2023.100257. eCollection 2023 Feb 8.
2
PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis.载脂蛋白 L3 基因型和糖尿病可识别非酒精性脂肪性肝病患者发生肝硬化的高风险。
Gastroenterology. 2023 May;164(6):966-977.e17. doi: 10.1053/j.gastro.2023.01.040. Epub 2023 Feb 7.
3
PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.PNPLA3 I148M与肝脂肪变性治疗反应：一项系统评价
Liver Int. 2023 May;43(5):975-988. doi: 10.1111/liv.15533. Epub 2023 Feb 16.
4
Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease.联合MRI-PDFF与ALT反应在预测非酒精性脂肪性肝病组织学反应中的临床应用
Clin Gastroenterol Hepatol. 2023 Sep;21(10):2682-2685.e4. doi: 10.1016/j.cgh.2022.08.036. Epub 2022 Sep 6.
5
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.代谢功能障碍和遗传风险因素在非酒精性脂肪性肝病发病机制中的不同贡献。
J Hepatol. 2022 Mar;76(3):526-535. doi: 10.1016/j.jhep.2021.10.013. Epub 2021 Oct 25.
6
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
7
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.与非酒精性脂肪性肝炎成人患者组织学应答相关的因素。
Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.
8
Next-generation genotype imputation service and methods.下一代基因型填充服务和方法。
Nat Genet. 2016 Oct;48(10):1284-1287. doi: 10.1038/ng.3656. Epub 2016 Aug 29.
9
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.利拉鲁肽治疗非酒精性脂肪性肝炎（LEAN）患者的安全性和有效性：一项多中心、双盲、随机、安慰剂对照的 2 期研究。
Lancet. 2016 Feb 13;387(10019):679-690. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20.
Zotero 插件